- Latest available (Revised)
- Original (As made)
There are currently no known outstanding effects for the The Medical Devices (Amendment etc.) (EU Exit) Regulations 2019, Section 9.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
9.—(1) Part VII of the 2002 Regulations is amended as follows.
(2) In regulation 59 M1(interpretation of Part VII)—
(a)omit the definition of “registrable device”;
(b)in the definition of “relevant device” after “IV” insert “ or a device for the purposes of Part VIII or IX. ”.
(3) M2In regulation 60 (designation etc. of authorised representatives)—
(a)for the heading substitute “ Status of UK responsible person ”;
(b)omit paragraphs (1) and (2);
(c)for paragraph (3), substitute—
“(3) A UK responsible person—
(a)may be proceeded against as a person placing the device on the market for the purposes of these regulations;
(b)in relation to the supply of the device to a person within the United Kingdom after it has been placed on the market, may be proceeded against as a person supplying the device after it has been placed on the market.”.
[F1(d)in paragraph (4)—
(i)for “an authorised representative of a manufacturer of a device” substitute “ a UK responsible person ”;
(ii)for “the single authorised representative of the manufacturer” substitute “ a UK responsible person ”.]
[F2(4) In regulation 61 (enforcement etc.)—
(a)for “CE marking” in both places substitute “UK marking”;
(b)in paragraph (8)(a)(i), after “essential requirement” insert “, a general safety and performance requirement”;
(c)in paragraph (8)(a)(ii), omit “set out in the Medical Devices Directives”;
(d)in paragraph (8)(a)(ii)(aa), for “his authorised representative” substitute “their UK responsible person”.]
(5) In regulation 62 (compliance notices) in paragraph (1)—
(i)after “performance evaluation” insert “ or study ”;
(ii)for “the manufacturer or his authorised representative” substitute “ any person ”;
[F3(iii)in sub-paragraph (c) omit “and, where applicable any relevant provision of the Medical Devices Directives”.]
(6) In regulation 63 M3 (restriction notices) in paragraph (1)—
(i)in sub-paragraph (a), after “performance evaluation” insert “ or study ”;
(ii)in sub-paragraph (b), after “performance evaluation” insert “ or study ”.
[F4(6A) In regulation 64 (notification of decisions etc)—
(a)in paragraph (1)(c), for “him or his authorised representative” substitute “the applicant or the applicant’s UK responsible person”;
(b)in paragraph (2)—
(i)for “a UK notified body” substitute “an approved body”;
(ii)for “his authorised representative” substitute “their UK responsible person”.]
(7) Omit regulation 65(centralised system of records etc.).
(8) In regulation 67 M4 (review), for “2019” substitute “ 2025 ”.
(9) Omit Schedule 1 M5 (association agreements).
(10) For Schedule 2 M6 (mutual recognition agreements) substitute—
Regulation 1A
— Australia
— New Zealand
— Canada
— The United States of America
— The Swiss Confederation”.
Textual Amendments
F1Reg. 9(3)(d) substituted (31.12.2020 immediately before IP completion day) by The Human Medicines and Medical Devices (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/1385), reg. 1, Sch. 2 para. 8; 2020 c. 1, Sch. 5 para. 1(1)
F2Reg. 9(4) substituted (31.12.2020 immediately before IP completion day) by The Medical Devices (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1478), reg. 1(3), Sch. 2 para. 51
F3Reg. 9(5)(iii) inserted (31.12.2020 immediately before IP completion day) by The Medical Devices (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1478), reg. 1(3), Sch. 2 para. 52
F4Reg. 9(6A) inserted (31.12.2020 immediately before IP completion day) by The Medical Devices (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1478), reg. 1(3), Sch. 2 para. 53
Commencement Information
I1Reg. 9(1)(3)-(10) in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1(1)
I2Reg. 9(2) in force at 1.5.2021, see reg. 1(2)(e) (as amended by S.I. 2020/1478, reg. 1(3), Sch. 2 para. 2(c))
Marginal Citations
M1Regulation 59 was amended by S.I. 2003/1697.
M2Regulation 60 was amended by S.I. 2008/2936.
M3Regulation 63 was amended by S.I. 2008/2936.
M4Regulation 67 was inserted by S.I. 2013/2327.
M5Schedule 1 was amended by 2013/2327.
M6Schedule 2 was amended by S.I. 2013/2327.
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
Impact Assessments generally accompany all UK Government interventions of a regulatory nature that affect the private sector, civil society organisations and public services. They apply regardless of whether the regulation originates from a domestic or international source and can accompany primary (Acts etc) and secondary legislation (SIs). An Impact Assessment allows those with an interest in the policy area to understand:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: